FindTrial
Sign In

Understanding the prevalence of antibiotic resistance and its treatment in hospital-acquired bloodstream infection cases

Prevalence and Rationale of Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) in Hospital Acquired Bloodstream Infection in Adult ICUs

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/09/045558
Enrollment
50
Registered
2022-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B968- Other specified bacterial agents as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Manipal Academy of Higher Education Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Patients admitted to ICU with suspicion of infection or with a blood culture positive report - Follow up records available

Exclusion criteria

Exclusion criteria: - Patients discharged against medical advice and or follow up not available - Adequate blood samples not available for culture

Design outcomes

Primary

MeasureTime frame
Identification of the prevalence of carbapenem resistance in Enterobacteriaceae.Timepoint: Baseline—

Secondary

MeasureTime frame
Analysing the patterns of carbapenem resistance in Enterobacteriaceae.Timepoint: 4 weeks—

Countries

India

Contacts

Public ContactMs Isha Mathur

Kasturba Medical College, Manipal

isha.mathur@learner.manipal.edu9910158864

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026